Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRSN | US
0.04
4.92%
Healthcare
Biotechnology
30/06/2024
24/04/2026
0.75
0.73
0.82
0.72
NeuroSense Therapeutics Ltd. a clinical-stage biotechnology company focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya Israel.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
43.2%1 month
62.1%3 months
66.2%6 months
84.4%-
-
4.15
-0.02
0.02
-1.16
-
-
-11.69M
14.86M
14.86M
-
-
-
-
-494.84
1.04
1.83
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.14
Range1M
0.18
Range3M
0.43
Rel. volume
1.85
Price X volume
155.70K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.5939 | 16.07M | 4.19% | n/a | 1.90% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.52 | 15.50M | 0.00% | n/a | 54.59% |
| iBio Inc | IBIO | Biotechnology | 1.68 | 15.35M | -7.18% | n/a | 20.92% |
| Lexaria Bioscience Corp | LEXX | Biotechnology | 0.9438 | 14.92M | 0.10% | n/a | 1.41% |
| Cocrystal Pharma Inc | COCP | Biotechnology | 1.43 | 14.55M | 1.42% | n/a | 10.24% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 0.94 | 13.50M | -3.73% | n/a | 11.72% |
| XTL Biopharmaceuticals Ltd | XTLB | Biotechnology | 2.43 | 13.24M | -0.61% | n/a | 0.00% |
| Genenta Science S.p.A | GNTA | Biotechnology | 0.7082 | 12.90M | 0.90% | n/a | 0.00% |
| JSPR | JSPR | Biotechnology | 0.8384 | 12.66M | -7.37% | n/a | 2.31% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.4 | 12.49M | -3.45% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.16 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.15 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 66.18 | 72.80 | Par |
| Debt to Equity | -0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 14.86M | 3.66B | Emerging |